GlassScriptPhysician profile
Mark R Jones
NPI 1851386767
$939.53
in general payments reported to CMS, 2019-2025
25 companies · $156 in 2025
The $156 reported for 2025 was less than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47.33 · 2023: $22.28 · 2024: $714 · 2025: $156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $892.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $892.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $228.64 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $70.27 | 2024-2025 | Keytruda, Welireg, Reblozyl |
| Janssen Biotech, INC. | $63.55 | 2024-2025 | Erleada, Carvykti |
| Astrazeneca Pharmaceuticals LP | $51.99 | 2019-2025 | Tagrisso |
| E.R. Squibb & Sons, L.L.C. | $49.13 | 2024 | Opdivo, Opdualag |
| Agios Pharmaceuticals, INC. | $42.60 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $41.98 | 2024 | Libtayo |
| Abbvie INC. | $38.08 | 2024 | |
| Sumitomo Pharma America, INC. | $37.45 | 2024 | Orgovyx |
| Jazz Pharmaceuticals INC. | $28.77 | 2024 | |
| Lilly USA, LLC | $24.85 | 2024 | Verzenio, Jaypirca, Retevmo |
| Incyte Corporation | $23.48 | 2024 | Jakafi |
| Novocure INC. | $23.28 | 2024 | Optune Lua (Novottf-200t) |
| Genmab U.S., INC. | $23.24 | 2024 | Tivdak |
| Pfizer INC. | $22.85 | 2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $22.28 | 2023 | Aixplorer Ultimate |
| Alexion Pharmaceuticals, INC. | $20.31 | 2024 | Ultomiris |
| Genentech USA, INC. | $18.80 | 2024 | Venclexta |
| Blueprint Medicines Corporation | $18.08 | 2024 | Ayvakit |
| Sobi, INC | $16.01 | 2024 | |
| Kyowa Kirin, INC. | $15.73 | 2024 | Poteligeo |
| Adaptive Biotechnologies Corporation | $15.42 | 2025 | Clonoseq |
| Adc Therapeutics America, INC. | $14.88 | 2024 | |
| Secura Bio, INC. | $14.52 | 2024 | Copiktra |
| Advanced Accelerator Applications | $13.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.